Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma

Sonidegib was administered orally at a dose of 200 mg once daily as per approved guidelines. The intervention was applied in a real-world clinical setting to patients with histologically confirmed, locally advanced periocular basal cell carcinoma (laBCC) deemed unsuitable for surgical resection or radiotherapy due to the tumor's extent or proximity to critical ocular structures. A flexible, individualized dose modulation strategy was implemented to manage adverse effects and optimize patient adherence. Modifications included temporary treatment interruptions or reduced dosing frequency, tailored to each patient's clinical status and tolerance. The goal of the intervention was to achieve local tumor control while preserving ocular structures, visual function, and cosmetic appearance. All patients received regular multidisciplinary follow-up, including ophthalmologic and dermatologic assessments.